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Abstract
Previous precision medicine studies have investigated conventional molecular techniques and/or limited sets of
gene alterations. The aim of this study was to describe the impact of the next-generation sequencing of the largest
panel of genes used to date in tumour tissue and blood in the context of institutional molecular screening
programmes. DNA analysis was performed by next-generation sequencing using a panel of 426 cancer-related
genes and by comparative genomic hybridization from formalin-fixed and paraffin-embedded archived tumour
samples when available or from fresh tumour samples. Five hundred sixty-eight patients were enrolled. The median
number of prior lines of treatment was 2 (range 0–9). The most common primary tumour types were lung (16.9%),
colorectal (14.4%), breast (10.6%), ovarian (10.2%) and sarcoma (10.2%). The median patient age was 63 years (range
19–88). A total of 292 patients (51.4%) presented with at least one actionable genetic alteration. The 20 genes most
frequently altered were TP53, CDKN2A, KRAS, PTEN, PI3KCA, RB1, APC, ERBB2, MYC, EGFR, CDKN2B, ARID1A, SMAD4,
FGFR1, MDM2, BRAF, ATM, CCNE1, FGFR3 and FRS2. One hundred fifty-nine patients (28%) were included in early
phase trials. The treatment was matched with a tumour profile in 86 cases (15%). The two main reasons for
non-inclusion were non-progressive disease (31.5%) and general status deterioration (25%). Twenty-eight percent
of patients presented with a growth modulation index (time to progression under the early phase trial
treatment/time to progression of the previous line of treatment) >1.3.
Extensive molecular profiling using high-throughput techniques allows for the identification of actionable
mutations in the majority of cases and is associated with substantial clinical benefit in up to one in four patients.
Letter to the editor
Previous precision medicine studies have investigated
conventional molecular techniques and/or limited sets
of gene alterations [1–3]. We describe here the impact
of the next-generation sequencing of the largest panel of
genes used to date in tumour tissue and blood in the
context of institutional molecular screening programmes.
The eligibility criteria, methods of sequencing and statis-
tics are described in Additional file 1.
Between January 1, 2014, and June 30, 2015, 568
patients were enrolled in the study. Their characteristics
are summarized in Additional file 2: Table S1 and
Additional file 3: Figure S1.
In 28 cases (5%), molecular analysis failed mainly because
of insufficient tissue quantity or quality. The median time
from first referral to reporting was 9 weeks (range 1–
36 weeks). The 20 genes found most frequently altered were
TP53, CDKN2A, KRAS, PTEN, PI3KCA, RB1, APC, ERBB2,
MYC, EGFR, CDKN2B, ARID1A, SMAD4, FGFR1, MDM2,
BRAF, ATM, CCNE1, FGFR3 and FRS2 (Additional file 4:
Figure S2). One thousand and six hundred fifty-nine alter-
ations were found: 883 mutations (53.2%), 755 (45.5%) gene
copy number alterations and 21 (1.3%) fusions. The median
number of alterations per patient was 2 (range 0–18).
Two hundred ninety-two (51.4%) patients had at least
one genetic alteration that was considered actionable by
the molecular tumour board. Molecular profiles by
tumour type are presented in Additional file 5: Figure S3.
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One hundred fifty-nine (28%) patients were random-
ized in an early phase clinical trial (EPCT) after the
screening results. The main reasons for non-inclusion
were non-progressive disease on current treatment regi-
men (31.5%), general status deterioration (25%), death
(16.5%), clinical trial not available (10.5%), screening fail-
ure (6.5%), loss to follow-up (7%) and patient refusal
(3%). The drug used in the EPCT was genotype-matched
(GM) in 86 (15.1%) patients and non-matched (NM) in
73 (12.9%) patients (Fig. 1). The drugs received are
summarized in Additional file 2: Table S2.
In the GM group, 65 patients were evaluable for the
response to treatment analysis. The disease control rate
(objective response rate + stable disease) was 47.7%
(Additional file 2: Table S3). The median progression-
free survival (PFS) was 3 months. The median overall
survival was 8.5 months (range 5.5–11.5 months).
Fifty-nine patients were evaluable for the growth mod-
ulatin index (GMI) calculation. The median GMI [4]
was 0.63 (0.01–5.81). Twenty patients (27.8%) had a
GMI ≥ 1.3 (Additional file 2: Table S3). A GMI ≥ 1.3 was
associated with a trend towards improved median overall
survival: 11.7 months (range 0.3–23.1) versus 7.6 months
(range 4.8–10.5 months) for GMI < 1.3, which was not
statistically significant (p = 0.28).
Thirty-nine patients with coupled primary and meta-
static tumours were analysed to evaluate the correlation
between the molecular screening results of the two sam-
ples. Twenty-six patients (67%) had at least one mutation
considered targetable. In this population, 9 cases had
a discordant mutational status between the primary
and metastatic sites. This discordance was related to
an actionable mutation in only four cases for a final
concordance rate in terms of targetable alterations of
85% (22/26 patients).
Seventy-five patients underwent also a tumour mo-
lecular profile-based circulating-free DNA (cfDNA)
analysis. Their characteristics are shown in Additional
file 2: Table S4. Ninety-five genetic aberrations were
found: 86 (90.5%) mutations, 7 (7.4%) gene copy
number alterations and 2 (2.1%) fusions. Thirty-four
(45.3%) patients were found to have at least one
targetable mutation (median number 1; range 0–5).
The most frequently altered genes are shown in
Additional file 6: Figure S4. Ten patients (13.3%) were
included in an EPCT, six (8%) of whom were included
based on their tumour genotype profiles.
Our extensive molecular screening program allowed
the identification of at least one actionable genetic
alteration in 51.4% of cases and was associated with a
significant clinical benefit since 27.8% of the patients in
the GM group experienced a GMI > 1.3 (Additional
file 2: Table S3). The low rate of technical failure and
the high correlation rate between primary tumours
and metastases demonstrate that FFPE archival tissue could
be used effectively for molecular screening, making the
need for invasive, resource-consuming and expensive
tumour biopsies unnecessary. Due to tumour heterogeneity,
Fig. 1 Study flow diagram
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biopsies often suffer from sample bias and archival tissue is
not always available. In this regard, we report here for the
first time the value of an NGS assay targeting 20 cancer
genes to detect actionable mutations and rearrangements
in cfDNA in the context of a precision medicine study.
Overall, this study demonstrates the feasibility and
potentially positive clinical impact of using comprehen-
sive molecular profiling to improve the outcomes of
cancer patients.
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